The National Organization for Rare Disorders (NORD®) has announced its distinguished slate of honorees for the annual NORD Rare Impact Awards®. This year’s recipients span the biopharma industry, medical research community, and patient advocacy landscape, recognized collectively for their profound contributions to improving the lives of the more than 30 million Americans currently living with a rare disease.
The 2026 honorees represent a diverse cross-section of the rare disease ecosystem. They include innovative companies whose groundbreaking treatments have fundamentally shifted patient outcomes, community leaders working tirelessly to raise public awareness, trailblazing scientists pushing the boundaries of medical research, and dedicated advocates spearheading vital legislative and policy changes across their respective states.

Industry Innovators in Rare Disease
Among the most prominent categories are the industry innovators. This year, five companies and one nonprofit organization—working closely alongside impacted rare disease patient communities—are being celebrated for securing recent U.S. Food and Drug Administration (FDA) approvals for first-of-their-kind therapies.
With approximately 95% of the more than 10,000 known rare diseases still lacking an approved treatment, advancing scientific progress remains one of the greatest challenges in modern medicine. Pamela K. Gavin, NORD Chief Executive Officer, emphasized the gravity of these milestones. NORD is deeply proud to honor these companies and nonprofit organizations for pioneering new therapies and advancing research that can fundamentally change what is possible for individuals and families affected by these rare conditions. Their progress in addressing the unique clinical challenges of these disorders is also contributing vital knowledge, methodologies, and breakthroughs that help move science and the entire rare disease field forward.

The 2026 Industry Innovator honorees reflect a broad spectrum of medical breakthroughs. Mighty Therapeutics is being recognized for FORZINITY™, the first-ever therapy approved for Barth syndrome. Barth syndrome is an extremely rare, progressive, and life-limiting genetic condition that affects the mitochondria and is clinically proven to improve muscle strength and overall quality of life. Barth syndrome advocates, including NORD member the Barth Syndrome Foundation, pushed tirelessly for the development of this treatment for over a decade, helping to secure its accelerated approval. The arrival of FORZINITY brings renewed hope not only to Barth families but also to patients facing other rare mitochondrial diseases, who have lauded the approval as a major leap forward for clinical research and regulatory pathways.
Another notable industry honoree is UCB, recognized for KYGEVVI®, the first and only FDA-approved treatment for adults and children suffering from thymidine kinase 2 deficiency (TK2d) whose symptoms manifested at or before 12 years of age. Clinical data demonstrated that KYGEVVI reduced the risk of death by over 90%, with 75% of patients regaining at least one previously lost motor skill and many successfully reducing or entirely eliminating their reliance on ventilatory support. This approval was widely celebrated by NORD members, including the United Mitochondrial Disease Foundation, MitoAction, and the Muscular Dystrophy Association, all of which spent years investing heavily in foundational mitochondrial disease research.

Fondazione Telethon has also earned recognition for Waskyra™, a breakthrough gene therapy for Wiskott-Aldrich syndrome (WAS). Developed through decades of rigorous research at the San Raffaele Telethon Institute for Gene Therapy (SR-Tiget) in Milan, Italy, WAS is a genetically inherited form of primary immunodeficiency (PI) and the historic first PI to receive an FDA-approved gene therapy. Furthermore, Waskyra marks the first time a nonprofit organization has successfully developed and brought to market an FDA-approved gene therapy, a milestone celebrated by NORD member the Immune Deficiency Foundation.
In the realm of oncology and transplant medicine, Omeros is being honored for YARTEMLEA®, the first and only FDA-approved treatment for adults and children aged two and older with hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). This condition is a severe and frequently fatal complication of stem cell transplantation, resulting from endothelial cell injury that causes blood clots in small blood vessels and damages vital organs. Bone marrow transplant advocacy groups and specialized medical institutions have hailed YARTEMLEA as a targeted and potentially life-saving intervention.

Jazz Pharmaceuticals is being recognized for MODEYSO™, the first and only FDA-approved treatment for recurrent H3K27M-mutant diffuse midline glioma (DMG), one of the most aggressive and devastating brain tumors impacting children and young adults. Approximately 2,000 Americans and their families receive this harrowing rare cancer diagnosis each year. The patient community spent more than a decade funding and participating in the foundational research that made this breakthrough possible. By securing accelerated approval for a new treatment pathway, Jazz Pharmaceuticals has offered patients and families the possibility of a new future.
Rounding out the industry category, Verastem Oncology is being honored for the AVMAPKI® FAKZYNJA® CO-PACK, the first treatment specifically approved for adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) who have previously received systemic therapy. This rare cancer carries a profound unmet medical need, with fewer than 14% of patients responding to traditional chemotherapy and hormone therapy. With an impressive response rate of 44%, the administration of this co-pack, alongside routine molecular testing for KRAS, is expected to establish a new standard of care for LGSOC in the near future.

Individuals and Organizations Honored
Beyond the biopharmaceutical sector, NORD proudly recognizes the individuals and organizations dedicated to improving daily life for the one in 10 Americans living with a rare disorder.
The Foundation for Prader-Willi Research (FPWR) has been named the recipient of the Abbey S. Meyers Leadership Award. As a NORD member organization, FPWR leads patient-centered research into Prader-Willi syndrome (PWS) through its Global PWS Registry, which was constructed using NORD’s IAMRARE® patient registry platform. Insights gathered directly from this registry contributed to last year’s landmark FDA approval of VYKAT™ XR, the first approved treatment addressing excessive hunger in adults and children with PWS—one of the disorder’s most challenging hallmark symptoms. This milestone represented the first known instance of IAMRARE data directly contributing to an FDA approval.

Dr. Stephanie E. Haridopolos, a board-certified family medicine physician and prominent public health official, is the recipient of the Policy Changemaker Award. Dr. Haridopolos has built a distinguished career spanning clinical practice and high-level government service, serving first as Chief of Staff of the Office of the Surgeon General and subsequently as its Director of National Health Communications. She has emerged as a critical voice for rare disease patients, most notably helping facilitate the Department of Health and Human Services’ addition of Duchenne muscular dystrophy and metachromatic leukodystrophy to the Recommended Newborn Screening Panel (RUSP). Since May 2026, Dr. Haridopolos has also performed the interim duties of the Surgeon General in the absence of a Senate-confirmed nominee.
A Community Champion Award has been presented to Dr. Julieta Bonvin Sallago of Connecticut. An international medical graduate who lives with a rare disease herself, Dr. Sallago is pursuing a career as a genetic counselor in the United States. She works in clinical trial recruitment at Connecticut Children’s Hospital for the Glycogen Storage Disease Program—the exact family of disorders for which she received her own diagnosis. Dr. Sallago has leveraged her scientific and cultural expertise to become a leader within NORD’s volunteer community, supporting the planning and execution of Latino patient and family listening sessions, translating NORD Rare Disease Reports into Spanish, and serving on the advisory committee for the NORD® Living Rare Study.

Lily Emmanuel of Colorado has also received a Community Champion Award for her passionate advocacy and volunteer leadership aimed at expanding rare disease awareness and strengthening community connections across the western United States. Through her work with NORD Running for Rare® in Colorado, Emmanuel has created inclusive opportunities for individuals impacted by rare diseases to escape isolation, engage in advocacy, and participate in fundraising through wellness initiatives. She has successfully forged relationships with hospitals, nonprofit organizations, local running groups, and patient communities to broaden rare disease education and support.
Dr. Maureen Helgren of Connecticut is another Community Champion Award recipient, recognized for transforming rare disease education by integrating it directly into the core curriculum at the Frank H. Netter, MD School of Medicine at Quinnipiac University. Dr. Helgren developed a dedicated rare disease course, founded the annual Netter Rare Disease Symposium, and consistently brings patients and advocates into the classroom to ensure future physicians understand both the clinical and lived realities of rare conditions. Serving as the faculty advisor for Quinnipiac University’s NORD Students for Rare® chapter, she has enabled students to participate in NORD’s annual Rare Diseases and Orphan Products Breakthrough Summit® in Washington, D.C.

In the medical and scientific domain, Dr. Susan A. Berry of Minnesota has been honored with a Medical & Scientific Trailblazer Award. Her career at the University of Minnesota Medical School NORD Rare Disease Center of Excellence exemplifies excellence in advancing rare disease research, diagnosis, and treatment at scale. Her work on inborn errors of metabolism, developed alongside patient advocates such as NORD member the National PKU Alliance, has defined a vital model of clinical care. Dr. Berry has also served as an advisor on newborn screening policies and an advocate for medical foods and formulas nationally, while maintaining active roles on NORD’s Board of Directors and Scientific & Medical Advisory Committee.
Dr. Stephen Kingsmore of California, the Founding President and CEO of the Rady Children’s Institute for Genomic Medicine—a NORD Rare Disease Center of Excellence at UC San Diego Rady Children’s Health—is a fellow recipient of the Medical & Scientific Trailblazer Award. Dr. Kingsmore has pioneered whole genome sequencing, established rapid genetic testing as a routine clinical tool, and developed the first comprehensive genomic carrier screening test. Recognizing that approximately 80% of rare diseases are genetic in origin, he is currently working to bring genetic screening and precision medicine to a wider array of clinics through emerging digital platforms.

Mark Skinner, JD, of New York has been honored with the Lifetime Achievement Award for his extensive history of leadership in bleeding disorders advocacy at state, national, and international levels. Skinner has led both the World Federation of Hemophilia and the National Bleeding Disorders Foundation, a NORD member organization, and has advised on critical blood safety matters as a member of the U.S. Health and Human Services Advisory Committee on Blood and Tissue Safety and Availability. As a champion of patient-centered outcomes research and principal investigator for the international PROBE study, Skinner continues to ensure that the actual experiences of patients inform high-level healthcare decision-making.
Paridhi Tyagi of New Jersey is the recipient of the Youth Leadership Award. Tyagi founded a high school genetics club during her sophomore year and partnered with NORD Students for Rare to educate her peers about genetic conditions. For Rare Disease Day 2024, she organized a local library awareness display and coordinated the sharing of patient stories via her school’s morning announcements. Recognizing the importance of engaging younger audiences, Tyagi spent nearly a year establishing a collaboration with Girl Scouts USA focused on genetics and rare disease education, culminating in hands-on workshops that taught participants about inclusion and the underlying science of genetics. Her dedication was further demonstrated by her participation at the NORD Breakthrough Summit as the sole high school student attending professional-level sessions.

Each of these 2026 Rare Impact Award winners demonstrates the power we each have as individuals to drive change in our communities, whether that’s as an advocate, policymaker, scientist, or physician, Gavin noted. They inspire us all to persevere in our shared mission to alleviate the physical, emotional, and financial strain that rare diseases place on too many individuals and families.
The Community Champion, Policy Changemaker, Youth Leader, Lifetime Achievement, and Abbey S. Meyers Leadership awardees will be recognized in person at the NORD Breakthrough Summit® in Washington, D.C. Meanwhile, the Scientific and Medical Trailblazer awardees were celebrated earlier this year at the NORD® Rare Disease Scientific Symposium, and NORD CEO Pamela Gavin is personally presenting the Industry Innovation Awards to each recipient company and their staff at their respective U.S. headquarters.
